VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors-- --Veru Plans to Meet with FDA and Advance VERU-111 into a Phase 2b Clinical Trial in Women with Paclitaxel Resistant Triple Negative Breast Cancer in 2021-- MIAMI, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announces the presentation of pre...
Source: marketscreener.com